Testosterone Cypionate: A Complete Research Guide

Testosterone cypionate is among the most extensively characterized long-acting androgen esters in the clinical and research literature. First introduced in the United States in the 1950s, it remains the reference ester for intramuscular testosterone replacement protocols across North America, and much of the pharmacokinetic data cited in modern research frameworks derives from studies using the cypionate ester specifically. This guide summarizes what published work reports about its ester kinetics, typical dose ranges in research and clinical contexts, injection frequency, aromatization behavior, and how it compares with the closely related enanthate ester.

Ester chemistry and release kinetics

Testosterone cypionate is testosterone esterified at the 17-beta hydroxyl group with cyclopentylpropionic acid, producing an eight-carbon side chain. The ester itself is pharmacologically inert; once injected intramuscularly into an oil depot, esterases in plasma and tissues hydrolyze the molecule to release free testosterone over a prolonged window. The length and lipophilicity of the cypionate side chain is what determines the release curve, not any intrinsic property of the testosterone molecule.

Published pharmacokinetic work generally reports a terminal half-life for testosterone cypionate in the range of approximately eight days, with some studies citing values between seven and nine days depending on the population studied, the oil vehicle used, and the injection site. Peak serum testosterone following a single intramuscular dose typically occurs within 24 to 72 hours, after which levels decline in a roughly exponential fashion. By day seven to ten, concentrations in most subjects have fallen to a fraction of peak, which is why weekly or more frequent administration schedules are standard in longitudinal protocols.

Researchers working with cypionate should note that a single-dose half-life does not map cleanly onto steady-state behavior. In repeated-dose protocols, accumulation occurs over roughly four to five half-lives, meaning that steady-state serum testosterone is typically reached after four to six weeks of consistent weekly dosing. Early-week and late-week serum draws during this accumulation phase can show wide intra-subject variance.

US-market preference and regional availability

Testosterone cypionate holds a distinctive position in the North American market. In the United States, it is the dominant long-acting testosterone ester used in clinical TRT practice, and most FDA-approved injectable testosterone products in that market are cypionate-based. Enanthate, by contrast, is more commonly the default ester in European clinical practice and in much of the rest of the world. The reasons for this split are largely historical and regulatory rather than pharmacological — the two esters are close substitutes in almost every meaningful respect.

This regional preference has downstream consequences for the research literature. A disproportionate share of the North American clinical studies on long-acting testosterone replacement — including much of the hypogonadism, body-composition, and erythrocytosis-monitoring work — is conducted using cypionate. European trials more often use enanthate or undecanoate. When reading across studies, researchers should be aware that differences attributed to "testosterone therapy" in one paper versus another may partially reflect the ester chosen and its dosing cadence, not the underlying pharmacology of testosterone itself.

For research-compound sourcing, cypionate and enanthate are typically interchangeable on a milligram-for-milligram basis for planning purposes, though the slightly longer half-life of cypionate can justify marginally less frequent injections if a protocol is designed around trough management.

Dose ranges reported in the literature

Reported dose ranges fall into two broad tiers, and it is important to keep them separate.

Clinical TRT range. Clinical hypogonadism protocols typically use 100 to 200 mg per week, often administered as a single weekly injection or split into two doses. A 2018 review of TRT pharmacokinetics summarized by Bhasin and colleagues in the Endocrine Society clinical practice guideline reported that weekly doses in this range generally produce mid-normal to upper-normal range serum testosterone at trough, with peaks that may transiently exceed the upper reference range in the first 24 to 48 hours post-injection. Dose titration in this range is typically guided by trough serum testosterone, hematocrit, and estradiol.

Supraphysiologic research range. In research contexts examining anabolic responses, body-composition change, or performance parameters, the literature describes weekly dose ranges extending from approximately 250 mg up to 600 or 750 mg per week. The often-cited 1996 Bhasin et al. study published in the New England Journal of Medicine used 600 mg of testosterone enanthate weekly in healthy men and documented measurable increases in lean mass and strength relative to placebo, both with and without a resistance training stimulus. Because cypionate and enanthate have very similar pharmacokinetic profiles, results from enanthate studies are routinely generalized to cypionate in research frameworks, though cross-ester replication is not always performed.

Dose-response data at the upper end of the research range is sparser and more variable, and supraphysiologic dosing is associated with a dose-dependent increase in adverse markers — hematocrit, blood pressure, lipid shifts, and suppression of endogenous hypothalamic-pituitary-gonadal axis function. The literature is consistent that these effects scale with dose.

Injection frequency: weekly versus E3.5D

Cypionate's approximate eight-day half-life produces a meaningful peak-to-trough ratio on a once-weekly injection schedule. Serum testosterone can vary by a factor of roughly two to three between the immediate post-injection peak and the day-seven trough in many subjects. For clinical TRT, this is generally acceptable, but a subset of subjects report symptomatic variation — energy, mood, and libido tracking the curve — and some practitioners split the weekly dose.

Two common schedules appear in the literature and in practitioner-reported protocols:

• Once weekly (Q7D). Simplest, lowest injection burden, but largest peak-to-trough swing. Typical for standard TRT at the lower end of the clinical range.
• Twice weekly, every 3.5 days (E3.5D). Splitting the weekly total into two injections spaced 3.5 days apart approximately halves the peak-to-trough ratio. This schedule is commonly used in research protocols at moderate to high weekly totals, and in clinical TRT where subjects report symptomatic swings on a once-weekly protocol.

Some protocols use every-other-day or even daily subcutaneous administration of smaller doses to further flatten the curve. Subcutaneous administration of testosterone cypionate has been documented in a growing body of clinical work, including a 2018 study by Kaminetsky and colleagues that reported comparable pharmacokinetic outcomes to intramuscular administration with a smoother profile and generally well-tolerated injection-site response.

The choice of schedule is a trade-off between injection burden and serum stability. For research protocols where steady-state serum testosterone is an independent variable being controlled, more frequent administration is generally preferred.

Aromatization and AI pairing

Testosterone is a substrate for the aromatase enzyme, which converts a fraction of circulating testosterone to estradiol. The cypionate ester does not modify this conversion — aromatization behavior of cypionate is identical to that of any other testosterone ester once the parent testosterone is liberated. What differs across esters is only the serum testosterone curve, and therefore the serum estradiol curve that tracks it.

At physiologic replacement doses (100 to 200 mg weekly), serum estradiol in most subjects rises within the normal male reference range and does not typically require pharmacologic management. At supraphysiologic research doses, estradiol scales with testosterone, and reported side effects associated with elevated estradiol — including water retention, gynecomastia-related tissue sensitivity, and mood shifts — become more prominent in the literature.

Aromatase inhibitors, most commonly anastrozole (Arimidex), are frequently paired with supraphysiologic testosterone protocols in the research literature to manage estradiol. Dose ranges for anastrozole reported in research contexts are typically in the range of 0.25 to 1 mg every few days, titrated against serum estradiol measurements. Researchers should note that aggressive aromatase inhibition carries its own risks — estradiol is not a waste product, and suppressing it below physiologic levels is associated in published work with adverse lipid changes, reduced bone mineral density over time, joint discomfort, and impaired libido and erectile function. The prevailing view in the clinical literature is that estradiol should be managed to a target range rather than minimized.

For cypionate specifically, the slower decay curve means estradiol also decays more slowly than with shorter esters, which can make AI dose titration more forgiving — adjustments take longer to manifest but also longer to wash out.

Cross-compatibility with testosterone enanthate

Testosterone cypionate and testosterone enanthate are pharmacologically the most similar pair of commonly used long-acting testosterone esters. Both are oil-depot injectables, both produce a similar serum testosterone profile after intramuscular injection, and both are dosed in approximately the same milligram ranges. Reported half-life differences are small — cypionate is typically cited at around eight days, enanthate at around seven — and in practice this difference is within the range of individual variability and is not clinically consequential for most protocols.

Key points of practical equivalence:

• Milligram conversion. A 1:1 milligram substitution between cypionate and enanthate is standard in the research literature. The active testosterone fraction of each ester differs by a trivial amount (cypionate is approximately 69 to 70 percent testosterone by mass, enanthate approximately 70 to 72 percent), and this is generally ignored outside of high-precision pharmacokinetic modeling.
• Injection schedule. Both are typically dosed weekly or E3.5D. No schedule change is required when substituting one for the other.
• Ancillary pairing. AI dosing does not need to be adjusted when switching esters.
• Crossover in protocols. Multi-week protocols that run out of one ester and substitute the other mid-run are commonly reported without measurable change in serum trajectory.

The choice between the two is generally driven by availability, regional market preference, and — in practitioner-reported contexts — injection-site comfort, which is often attributed to the specific oil vehicle rather than the ester itself.

Open questions

Several areas in the cypionate literature remain underspecified and worth flagging for researchers designing protocols.

The long-term cardiovascular risk profile of supraphysiologic testosterone dosing remains debated. The 2023 TRAVERSE trial, published in the New England Journal of Medicine, reported no increased incidence of major adverse cardiovascular events in hypogonadal men treated with testosterone at clinical replacement doses over a mean follow-up of approximately two years, but this result does not extend to the supraphysiologic range used in research contexts, and longer-horizon data is limited.

Subcutaneous administration of cypionate is increasingly reported in clinical practice, but head-to-head pharmacokinetic comparisons across different oil vehicles, needle gauges, and injection volumes are sparse. The assumption that subcutaneous and intramuscular administration produce equivalent steady-state exposure is based on a small number of studies and would benefit from replication.

The interaction between cypionate-based protocols and oral 17-alpha-alkylated compounds — hepatotoxicity, lipid effects, and blood pressure — is widely discussed in practitioner-reported frameworks but thinly studied in controlled clinical work. Researchers designing stacked protocols should treat the available evidence as preliminary and monitor standard safety markers at appropriate intervals.

Finally, optimal estradiol target ranges during supraphysiologic testosterone protocols are not well-established. Most published guidance derives from TRT-range studies, and extrapolation to higher testosterone exposures is an inference, not a measured finding.